
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/139173/publications.pdf Version: 2024-02-01



KOEN DOESEN

#	Article	IF	CITATIONS
1	Respiratory onset of amyotrophic lateral sclerosis in a pregnant woman with a novel <i>SOD1</i> mutation. European Journal of Neurology, 2022, 29, 1279-1283.	1.7	2
2	Prognostic relationship of neurofilaments, CHIT1, YKL-40 and MCP-1 in amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 681-682.	0.9	7
3	Phosphoâ€specific plasma pâ€ŧau181 assay detects clinical as well as asymptomatic Alzheimer's disease. Annals of Clinical and Translational Neurology, 2022, 9, 734-746.	1.7	11
4	Biochemical and clinical biomarkers in adult <scp>SMA</scp> 3–4 patients treated with nusinersen for 22 months. Annals of Clinical and Translational Neurology, 2022, 9, 1241-1251.	1.7	12
5	Prognostic value of neurofilament light chain in chronic inflammatory demyelinating polyneuropathy. Brain Communications, 2021, 3, fcab018.	1.5	7
6	Chitotriosidase as biomarker for early stage amyotrophic lateral sclerosis: a multicenter study. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, 22, 276-286.	1.1	14
7	Detection of multiple myositis-specific autoantibodies in unique patients with idiopathic inflammatory myopathy: A single centre-experience and literature review. Seminars in Arthritis and Rheumatism, 2021, 51, 486-494.	1.6	8
8	Altered perivascular fibroblast activity precedes ALS disease onset. Nature Medicine, 2021, 27, 640-646.	15.2	69
9	Prognostic value of amyloid/tau/neurodegeneration (ATN) classification based on diagnostic cerebrospinal fluid samples for Alzheimer's disease. Alzheimer's Research and Therapy, 2021, 13, 84.	3.0	26
10	Neuropathy of the phrenic nerve associated with antiganglioside antibodies. European Journal of Neurology, 2021, 28, 2138-2141.	1.7	1
11	Determination of free light chains: assay-dependent differences in interpretation. Clinical Chemistry and Laboratory Medicine, 2021, 59, e69-e71.	1.4	1
12	Prognostic value of amyloid/tau/neurodegeneration (ATN) classification based on diagnostic cerebrospinal fluid samples for Alzheimer's disease. Alzheimer's and Dementia, 2021, 17, .	0.4	0
13	Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview. Alzheimer's and Dementia, 2021, 17, .	0.4	7
14	Intervalâ€specific likelihood ratios for improving differential diagnosis of Alzheimer's disease using biomarkers in cerebrospinal fluid. Alzheimer's and Dementia, 2021, 17, .	0.4	0
15	Antinuclear antibodies by indirect immunofluorescence and solid phase assays. Annals of the Rheumatic Diseases, 2020, 79, e65-e65.	0.5	21
16	Comparison of ELISA- and SIMOA-based quantification of plasma AÎ <sup>2</sup> ratios for early detection of cerebral amyloidosis. Alzheimer's Research and Therapy, 2020, 12, 162.	3.0	58
17	Dipeptide repeat protein and TDP-43 pathology along the hypothalamic–pituitary axis in C9orf72 and non-C9orf72 ALS and FTLD-TDP cases. Acta Neuropathologica, 2020, 140, 777-781.	3.9	8
18	Comparison of two analytical platforms for bloodâ€based surrogate biomarkers of amyloid pathology. Alzheimer's and Dementia, 2020, 16, e045110.	0.4	0

#	Article	IF	CITATIONS
19	Use of Multimodal Imaging and Clinical Biomarkers in Presymptomatic Carriers of <i>C9orf72</i> Repeat Expansion. JAMA Neurology, 2020, 77, 1008.	4.5	45
20	A multi-center study of neurofilament assay reliability and inter-laboratory variability. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 452-458.	1.1	15
21	Neurofilament light chain and C reactive protein explored as predictors of survival in amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 436-437.	0.9	25
22	Comparison of 2 Serum-Free Light-Chain Assays in CKD Patients. Kidney International Reports, 2020, 5, 627-631.	0.4	13
23	CHIT1 at Diagnosis Reflects Longâ€Term Multiple Sclerosis Disease Activity. Annals of Neurology, 2020, 87, 633-645.	2.8	22
24	Serum neurofilament light chain levels as a marker of upper motor neuron degeneration in patients with Amyotrophic Lateral Sclerosis. Neuropathology and Applied Neurobiology, 2019, 45, 291-304.	1.8	82
25	Serum neurofilament heavy chains as early marker of motor neuron degeneration. Annals of Clinical and Translational Neurology, 2019, 6, 1971-1979.	1.7	29
26	Harmonization of clinical interpretation of antinuclear antibody test results by solid phase assay and by indirect immunofluorescence through likelihood ratios. Autoimmunity Reviews, 2019, 18, 102386.	2.5	23
27	Inflammatory markers in cerebrospinal fluid: independent prognostic biomarkers in amyotrophic lateral sclerosis?. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, jnnp-2018-319586.	0.9	42
28	An ALS case with 38 (G4C2)-repeats in the C9orf72 gene shows TDP-43 and sparse dipeptide repeat protein pathology. Acta Neuropathologica, 2019, 137, 855-858.	3.9	12
29	Cerebrospinal fluid levels of synaptic and neuronal integrity correlate with gray matter volume and amyloid load in the precuneus of cognitively intact older adults. Journal of Neurochemistry, 2019, 149, 139-157.	2.1	10
30	Clinical spectrum of the anti-GQ1b antibody syndrome: a case series of eight patients. Acta Neurologica Belgica, 2019, 119, 29-36.	0.5	17
31	AB0696â€DETECTION OF COEXISTING MYOSITIS-SPECIFIC AUTOANTIBODIES WITH LINE AND DOT IMMUNOASSAYS IN PATIENTS WITH IDIOPATHIC INFLAMMATORY MYOPATHIES. , 2019, , .		0
32	Horizontal saccadic palsy as a prominent symptom of anti-NMDAR encephalitis. Neurology: Clinical Practice, 2019, 11, 10.1212/CPJ.0000000000000750.	0.8	0
33	Detection of myositis-specific antibodies. Annals of the Rheumatic Diseases, 2019, 78, e7-e7.	0.5	48
34	Diagnostic thresholds for free light chains in multiple myeloma depend on the assay used. Leukemia, 2018, 32, 1815-1818.	3.3	17
35	Antigen excess detection by automated assays for free light chains. Clinical Chemistry and Laboratory Medicine, 2018, 56, e235-e238.	1.4	4
36	Automation on an Open-Access Platform of Alzheimer's Disease Biomarker Immunoassays. SLAS Technology, 2018, 23, 188-197.	1.0	5

#	Article	IF	CITATIONS
37	Screening for connective tissue disease-associated antibodies by automated immunoassay. Clinical Chemistry and Laboratory Medicine, 2018, 56, 909-918.	1.4	31
38	Solid phase assays versus automated indirect immunofluorescence for detection of antinuclear antibodies. Autoimmunity Reviews, 2018, 17, 533-540.	2.5	57
39	Comparison of elevated phosphorylated neurofilament heavy chains in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 367-373.	0.9	86
40	Elevated ALS Biomarker Levels in CSF of a FTD Patient at the Presymptomatic Stage of ALS. Alzheimer Disease and Associated Disorders, 2018, 32, 156-157.	0.6	3
41	Multicenter evaluation of neurofilaments in early symptom onset amyotrophic lateral sclerosis. Neurology, 2018, 90, e22-e30.	1.5	148
42	The effect of xenonâ€augmented sevoflurane anesthesia on intraoperative hemodynamics and early postoperative neurocognitive function in children undergoing cardiac catheterization: A randomized controlled pilot trial. Paediatric Anaesthesia, 2018, 28, 726-738.	0.6	15
43	The Chromosomal Conformation Signature: A New Kid on the Block in ALS Biomarker Research?. EBioMedicine, 2018, 33, 6-7.	2.7	5
44	Tubulointerstitial expression and urinary excretion of connective tissue growth factor 3 months after renal transplantation predict interstitial fibrosis and tubular atrophy at 5 years in a retrospective cohort analysis. Transplant International, 2017, 30, 695-705.	0.8	10
45	Neurofilament markers for ALS correlate with extent of upper and lower motor neuron disease. Neurology, 2017, 88, 2302-2309.	1.5	169
46	Finger extension weakness and downbeat nystagmus motor neuron disease syndrome: A novel motor neuron disorder?. Muscle and Nerve, 2017, 56, 1164-1168.	1.0	14
47	Negative commercial screening test for paraneoplastic antibodies in a case of opsoclonus. Neurology: Neuroimmunology and NeuroInflammation, 2017, 4, e329.	3.1	1
48	Xenon as an adjuvant to sevoflurane anesthesia in children younger than 4Âyears of age, undergoing interventional or diagnostic cardiac catheterization: A randomized controlled clinical trial. Paediatric Anaesthesia, 2017, 27, 1210-1219.	0.6	10
49	Diagnostic Challenges and Clinical Characteristics of Hepatitis E Virus–Associated Guillain-Barré Syndrome. JAMA Neurology, 2017, 74, 26.	4.5	61
50	Homozygous N-terminal missense mutation in TRNT1 leads to progressive B-cell immunodeficiency in adulthood. Journal of Allergy and Clinical Immunology, 2017, 139, 360-363.e6.	1,5	41
51	Three Patients with an Unusual Pattern on Urine Immunofixation. Clinical Chemistry, 2016, 62, 1412-1413.	1.5	1
52	Two Cases of Heavy Chain MGUS. Case Reports in Oncological Medicine, 2016, 2016, 1-4.	0.2	4
53	P1-200: Improvement of Reproducibility for CSF Biomarker Analysis by Integration of Automation in the Test Procedures. , 2016, 12, P480-P481.		0
54	Multicenter validation of CSF neurofilaments as diagnostic biomarkers for ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2016, 17, 404-413.	1.1	84

#	Article	IF	CITATIONS
55	Evaluation of the V8 E-Class, a Novel Automated Capillary Isoelectric Focusing Instrument for Hemoglobinopathy Screening. American Journal of Clinical Pathology, 2016, 146, 361-368.	0.4	4
56	Xenon for the prevention of postoperative delirium in cardiac surgery: study protocol for a randomized controlled clinical trial. Trials, 2015, 16, 449.	0.7	14
57	Diagnostic value of cerebrospinal fluid Aβ ratios in preclinical Alzheimer's disease. Alzheimer's Research and Therapy, 2015, 7, 75.	3.0	47
58	Ecstasy intoxication as an unusual cause of epileptic seizures in young children. European Journal of Pediatrics, 2013, 172, 1547-1550.	1.3	12
59	Inhibition of Tumor Angiogenesis and Growth by a Small-Molecule Multi-FGF Receptor Blocker with Allosteric Properties. Cancer Cell, 2013, 23, 477-488.	7.7	138
60	Performance of cassette-based blood gas analyzers to monitor blood glucose and lactate levels in a surgical intensive care setting. Clinical Chemistry and Laboratory Medicine, 2013, 51, 1417-27.	1.4	10
61	Historical Response Factor–Based Quantification for LC-MS/MS. Clinical Chemistry, 2013, 59, 1674-1676.	1.5	1
62	Relapsing Brevibacterium casei Peritonitis: Value of 16S rRNA Gene Sequencing in Accurate Species Identification. Peritoneal Dialysis International, 2012, 32, 341-344.	1.1	9
63	Interference of ethylene glycol with lactate measurement: A comparison study on new generation cassette-based blood gas analyzers. Clinica Chimica Acta, 2012, 414, 18-19.	0.5	4
64	Systemic anti-vascular endothelial growth factor therapies induce a painful sensory neuropathy. Brain, 2012, 135, 2629-2641.	3.7	53
65	Neuronal FLT1 receptor and its selective ligand VEGFâ€B protect against retrograde degeneration of sensory neurons. FASEB Journal, 2011, 25, 1461-1473.	0.2	45
66	Matrix-Binding Vascular Endothelial Growth Factor (VEGF) Isoforms Guide Granule Cell Migration in the Cerebellum via VEGF Receptor Flk1. Journal of Neuroscience, 2010, 30, 15052-15066.	1.7	75
67	Impaired Autonomic Regulation of Resistance Arteries in Mice With Low Vascular Endothelial Growth Factor or Upon Vascular Endothelial Growth Factor Trap Delivery. Circulation, 2010, 122, 273-281.	1.6	37
68	VEGF protects motor neurons against excitotoxicity by upregulation of GluR2. Neurobiology of Aging, 2010, 31, 2185-2191.	1.5	78
69	Novel Role for Vascular Endothelial Growth Factor (VEGF) Receptor-1 and Its Ligand VEGF-B in Motor Neuron Degeneration. Journal of Neuroscience, 2008, 28, 10451-10459.	1.7	119
70	The naturally occurring N6-threonyl adenine in anticodon loop of Schizosaccharomyces pombe tRNAi causes formation of a unique U-turn motif. Nucleic Acids Research, 2006, 34, 2878-2886.	6.5	35